Background: G2013 molecule is a novel non-steroidal anti-inflammatory agent with immunosuppressive property, which was investigated on determinants relative to the oxidative stress in animal model. Materials and Methods: The Sprague-Dawley rats were used for evaluating properties of G2013 on some oxidative stress enzymes including: Myeloperoxidase (MPO), Glutathione peroxidase (GPX1), mitochondrial Superoxide dismutase (SOD2), Catalase (CAT), Glutathione S-Transferase (GST), and inducible nitric oxide synthase (iNOS) genes expression by Real Time PCR. The rats were sacrificed 3 months after daily oral administration of G2013. Moreover, Malondialdehyde (MDA), Carbonyl protein (PCO), the lipid and protein oxidation markers respectively and total anti-oxidant capacity (TAC) were tested in serum by biochemical analysis. Also cortisol as a steroid hormone was evaluated by chemiluminescence immunoassay after 12 weeks consumption of G2013 solution. Result: Our findings revealed a significant decrease in MPO in G2013 treated group, indicating its favorable effects but has no significant effects on genes expression of another antioxidant enzymes, including: SOD2, CAT, GPX1, and GST. Also, there were no significant differences in PCO, TAC and cortisol compared to control group following G2013 consumption. While an enhancement in serum MDA level was observed in the treatment group. In addition, G2013 therapy did not show any weight loss. Conclusions: Our data showed the safety and efficacy of G2013 as a novel designed NSAID on various oxidative stress determinants.
Keywords: CAT, cortisol, G2013, GPX1, GST, iNOS2, MDA, MPO, oxidative stress, PCO, ROS, SOD2, TAC.